Background: Nowadays, the downregulation of genes involved in the pathogenesis of severe lung diseases through local siRNA delivery appears an interesting therapeutic approach. In this study, we propose novel hybrid lipid-polymer nanoparticles (hNPs) consisting of poly(lactic-co-glycolic) acid (PLGA) and dipalmitoyl phosphatidylcholine (DPPC) as siRNA inhalation system. Methods: A panel of DPPC/PLGA hNPs was prepared by emulsion/solvent diffusion and fully characterized. A combination of model siRNAs against the sodium transepithelial channel (ENaC) was entrapped in optimized hNPs comprising or not poly(ethylenimine) (PEI) as third component. siRNA-loaded hNPs were characterized for encapsulation efficiency, release kinetics, aerodynamic properties, and stability in artificial mucus (AM). The fate and cytotoxicity of hNPs upon aerosolization on a triple cell co-culture model (TCCC) mimicking human epithelial airway barrier were assessed. Finally, the effect of siRNA-loaded hNPs on ENaC protein expression at 72 hours was evaluated in A549 cells. Results: Optimized muco-inert hNPs encapsulating model siRNA with high efficiency were produced. The developed hNPs displayed a hydrodynamic diameter of ∼150 nm, a low polydispersity index, a negative ζ potential close to-25 mV, and a peculiar triphasic siRNA release lasting for 5 days, which slowed down in the presence of PEI. siRNA formulations showed optimal in vitro aerosol performance after delivery with a vibrating mesh nebulizer. Furthermore, small-angle X-ray scattering analyses highlighted an excellent stability upon incubation with AM, confirming the potential of hNPs for direct aerosolization on mucus-lined airways. Studies in TCCC confirmed that fluorescent hNPs are internalized inside airway epithelial cells and do not exert any cytotoxic or acute proinflammatory effect. Finally, a prolonged inhibition of ENaC protein expression was observed in A549 cells upon treatment with siRNA-loaded hNPs. Conclusions: Results demonstrate the great potential of hNPs as carriers for pulmonary delivery of siRNA, prompting toward investigation of their therapeutic effectiveness in severe lung diseases.
Hybrid Lipid/Polymer Nanoparticles for Pulmonary Delivery of siRNA : Development and Fate Upon In Vitro Deposition on the Human Epithelial Airway Barrier / I. D'Angelo, G. Costabile, E. Durantie, P. Brocca, V. Rondelli, A. Russo, G. Russo, A. Miro, F. Quaglia, A. Petri-Fink, B. Rothen-Rutishauser, F. Ungaro. - In: JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY. - ISSN 1941-2711. - 31:3(2018 Jun), pp. 170-181.
|Titolo:||Hybrid Lipid/Polymer Nanoparticles for Pulmonary Delivery of siRNA : Development and Fate Upon In Vitro Deposition on the Human Epithelial Airway Barrier|
|Parole Chiave:||dipalmitoylphosphatidylcholine; inhalable nanoparticles; poly(ethylenimine); poly(lactic-co-glycolic) acid; siRNA; triple cell coculture|
|Settore Scientifico Disciplinare:||Settore FIS/07 - Fisica Applicata(Beni Culturali, Ambientali, Biol.e Medicin)|
|Data di pubblicazione:||giu-2018|
|Data ahead of print / Data di stampa:||16-ott-2017|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1089/jamp.2017.1364|
|Appare nelle tipologie:||01 - Articolo su periodico|
File in questo prodotto:
|JournalAerosolMedicine_HybridLipidPolymer_2017.pdf||Publisher's version/PDF||Open Access Visualizza/Apri|
|Manuscript_for green pub.pdf||Pre-print (manoscritto inviato all'editore)||Open Access Visualizza/Apri|